The DOT testing at HHS-certified laboratories is a 5-panel drug test regimen within DOT and non-DOT drug testing services. As of January 1, 2018, the ‘Opiates’ category was renamed ‘Opioids’:
Under ‘Opioids’, previously ‘Opiates’, DOT testing will continue to include confirmatory testing, when appropriate, for Codeine, Morphine, and 6-AM (heroin). We added initial and confirmatory testing for the semi-synthetic opioids Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone to this Opioids group. Some brand names for the semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, Exalgo®.
Under Amphetamines, DOT testing includes confirmatory testing, when appropriate, for Amphetamine, Methamphetamine, MDMA, and MDA. To this Amphetamines group, we added initial testing for MDA and removed testing for MDEA.
Since January 1st, we have required confirmation testing for 14 drugs under a 5‑panel test. Broken out, here is what DOT drug testing looks like:
For DOT testing, what does this mean for collectors, laboratories, MROs, and employers managing structured employer drug testing programs after January 1st 2018
DOT 5 panel testing is often part of broader compliance programs that may include additional testing services depending on the situation.DOT and non-DOT testing situations often require different types of services depending on timing, compliance requirements, and circumstances.
WeAssure Screening Services, Greater Kansas City
Reliable, Certified, Mobile.
WeAssure It.
Copyright © 2025 WeAssure Screening Services - All Rights Reserved.